An observational study in Heart Valve Diseases and Aortic Valve Insufficiency, sponsored by Duk-Woo Park, MD. Recruiting at 7 sites in 3 countries. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Duk-Woo Park, MD · Observational
This registry evaluates the long-term outcome of Transcatheter aortic valve replacement (TAVR) in real-world clinical practice.
This study is connected with Asian TAVR registry(NCT02308150). Some subjects from Asian TAVR registry continue 10 years follow-up on this TP-TAVR registry.
169 studies on the registry are indexed under Aortic Valve Insufficiency; 54 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 224 across 74 observational studies indexed under Aortic Valve Insufficiency.
Browse Aortic Valve Insufficiency studies →Duk-Woo Park, MD is the lead sponsor of 15 studies on the registry; 6 are open to participants now.
Compared within Aortic Valve Insufficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Valve Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
All patients undergoing TAVR
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Seoul, Korea All Patients undergoing TAVR
Procedure: TAVR
California, USA All Patients undergoing TAVR
Procedure: TAVR
Evanston, Illinois, USA All Patients undergoing TAVR
Procedure: TAVR
Taipei, Taiwan All Patients undergoing TAVR
Procedure: TAVR
transcatheter aortic valve replacement (TAVR)
Event rate of all cause death
Time frame: 1 year
Event rate of cardiovascular death
A. Death due to proximate cardiac cause B. Death caused by non-coronary vascular condition C. All procedure-related death D. All valve-related death E. Sudden or unwitnessed death F. Death of unknown cause
Time frame: 10 years
Event rate of myocardial infarction
according to Valve Academic Research Consortium (VARC) criteria
Time frame: 10 years
Event rate of cerebrovascular accident
stroke and TIA (Transient Ischemic Attack)
Time frame: 10 years
Event rate of bleeding
according to Valve Academic Research Consortium (VARC) criteria
Time frame: 10 years
Event rate of Vascular access site and access-related complication
according to Valve Academic Research Consortium (VARC) criteria
Time frame: 30 days
Event rate of Acute kidney injury
Time frame: 30 days
Event rate of Permanent pacemaker insertion
Time frame: 10 years
Event rate of Other TAVR-related complication
A. Conversion to open surgery B. Coronary obstruction C. Mitral valve apparatus damage or dysfunction D. Cardiac tamponade E. Endocarditis F. Valve thrombosis G. Valve mal-positioning H. TAV-in-TAV deployment
Time frame: 10 years
Event rate of Prosthetic valve dysfunction
according to Valve Academic Research Consortium (VARC) criteria A. Prosthetic aortic valve stenosis B. Prosthesis-patient mismatch C. Prosthetic aortic valve regurgitation
Time frame: 10 years
Event rate of Composite endpoint
A. Device success B. Early safety : death, cerebrovascular event, fatal bleeding, acute kidney injury, coronary obstruction requiring intervention, major vascular complication, valve dysfunction requiring intervention C. Clinical efficacy : death, cerebrovascular event, valve-related symptom requiring hospitalization or devastating heart failure, NYHA class\* III, IV dyspnea, valve dysfunction \*the New York Heart Association (NYHA) Functional Classification
Time frame: 10 years
Event rate of Structural valve deterioration
Time frame: 10 years
NYHA class
Time frame: 30 days
NYHA class
Time frame: 1 year
Valve area
Time frame: 1 year
Event rate of free from atrial fibrillation
Time frame: 10 years
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Duk-Woo Park, MD